Valneva initiates further phase 3 clinical trial for its covid-19 vaccine candidate

Saint-herblain (france), august 11th, 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the initiation of a further phase 3 trial (vla2001-304) for its inactivated, adjuvanted covid-19 vaccine candidate, vla2001.
VALN Ratings Summary
VALN Quant Ranking